earnings

2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
Motley Fool
Exelixis
earnings
Cabometyx
Flag link:
A Perfect Storm Cut Teva Pharmaceutical Industries's Stock in Half in August
A Perfect Storm Cut Teva Pharmaceutical Industries's Stock in Half in August
Motley Fool
Teva Pharmaceutical
earnings
Flag link:
Medtronic logs fiscal Q1 earnings beat, but sales miss the mark
Medtronic logs fiscal Q1 earnings beat, but sales miss the mark
Mass Device
Medtronic
devices
earnings
Flag link:
Tesaro's Zejula rolls to No. 1 PARP position with big Q2
Tesaro's Zejula rolls to No. 1 PARP position with big Q2
Fierce Pharma
Tesaro
Zejula
PARP inhibitors
earnings
Flag link:
BioDelivery Sciences beats Q2 rev estimates, misses on EPS
BioDelivery Sciences beats Q2 rev estimates, misses on EPS
Drug Delivery Business News
BioDelivery Sciences
earnings
Flag link:
Novo Nordisk profit flat; upbeat on sales outlook
Novo Nordisk profit flat; upbeat on sales outlook
Marketwatch
Novo Nordisk
earnings
Flag link:
3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
Yahoo/Zacks.com
earnings
Puma Biotechnology
Alnylam
Impax Labs
Flag link:
Mallinckrodt beats Q2 earnings, misses on revenue
Mallinckrodt beats Q2 earnings, misses on revenue
Drug Delivery Business News
Mallinckrodt
earnings
Flag link:
MannKind posts mixed Q2
MannKind posts mixed Q2
Drug Delivery Business News
MannKind
earnings
Flag link:
Endo swings to Q2 loss on $775m pelvic mesh set-aside
Endo swings to Q2 loss on $775m pelvic mesh set-aside
Drug Delivery Business News
Endo International
earnings
Flag link:
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
Motley Fool
GW Pharma
earnings
investors
Flag link:
bluebird bio Pauses During 2017 Data Blitz
bluebird bio Pauses During 2017 Data Blitz
Motley Fool
Bluebird Bio
gene therapy
earnings
ASH
Flag link:
These 3 Biotechs Just Crushed Analyst Expectations
These 3 Biotechs Just Crushed Analyst Expectations
Motley Fool
biotech
earnings
Sarepta Therapeutics
Biogen
Gilead Sciences
Flag link:
Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire
Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire
TheStreet.com
Pfizer
earnings
Allergan
M&A
Flag link:
Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday
Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday
Forbes
earnings
Valeant Pharmaceuticals
Flag link:
Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important
Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important
Motley Fool
Juno Therapeutics
JCAR017
earnings
Flag link:
Botox, fillers steal the show as Allergan posts Q2 beats
Botox, fillers steal the show as Allergan posts Q2 beats
Fierce Pharma
Allergan
earnings
Flag link:
Teva (TEVA) Q2 Earnings and Sales Miss, Shares Up
Teva (TEVA) Q2 Earnings and Sales Miss, Shares Up
Yahoo/Zacks.com
Teva Pharmaceutical
earnings
Flag link:
Regeneron Earnings, Revenue Top Views; Shares Down Slightly
Regeneron Earnings, Revenue Top Views; Shares Down Slightly
Investors Business Daily
Regeneron
earnings
Flag link:
Earnings Preview: What To Expect From Teva Pharmaceutical On Thursday
Earnings Preview: What To Expect From Teva Pharmaceutical On Thursday
Forbes
earnings
Teva Pharmaceutical
Flag link: